Compare Novo Nordisk A/S (NVO) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares Silver Trust — how do they compare? Novo Nordisk A/S trades at $44.8 (market cap $200.69B), while iShares Silver Trust trades at $60.58. The key difference: Novo Nordisk A/S pays a 3.98% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals.
| NVO | SLV | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | — |
52-Week High | $63.98 | $105.57 |
52-Week Low | $35.29 | $37.41 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SLV, the iShares Silver Trust ETF, trades at $59.37, down 0.75% on the day, with a bearish technical signal driven by moving averages. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver. Recent news highlights silver's volatility amid Fed policy uncertainty and geopolitical tensions, with institutional buying noted in Q2 2026 filings.
Outlook remains mixed: silver's structural deficit supports prices, but Fed rate risks and dollar fluctuations pose headwinds. Investors face volatility from industrial demand shifts and inflation data, with technical resistance near $60–$61 capping near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
